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In recent years, substantial changes in urological cancer-
related mortality have occurred. These have resulted from
therapeutic improvements of prostatic cancer, decreased
exposure to tobacco smoking, and occupational carcinogens
of bladder and possibly kidney cancers. Despite improved
primary prevention, detection, and treatment, the incidence
of age-related cancers of the urinary tract is likely to rise as
a result of global population ageing. Therefore, it is vital to
identify and address themost relevant targets for further early
detection, investigation, and therapy of urological malignan-
cies.
In keeping with this spirit, this special issue brings
articles that investigated clinical and prognostic significance
of several factors in the three most common urological
cancers: renal cell carcinoma, prostate cancer, and bladder
cancer.
G. Ji et al. in their report analysed pathological features
of 2,929 men diagnosed with prostate cancer within different
age groups including patients older than 75 years of age.They
found that both patients aged ≤55 years and >75 years are
more likely to be diagnosed with more aggressive disease.
These findings have certain consequences including more
aggressive treatment of the disease also in elderly healthymen
and bring us into opposition with supporters of nonradical
management of prostate cancer in older men.
Two research articles are dedicated to the prognostic
role of blood-derived factors in patients with renal cell
carcinoma. Y. Tian et al. in their systematic review and meta-
analysis provide an evidence for elevated plasma fibrinogen
to be adversely associated with overall, cancer-specific, and
disease-free survival. S.-S. Byun et al. assessed the prognostic
significance of preoperative neutrophil-to-lymphocyte ratio
in nonmetastatic renal cell carcinoma.Their findings showed
that the investigated parameter was associated with worse
clinical tumour behavior, and it was a significant prognostic
factor for both recurrence-free and cancer-specific survival in
that group of patients.
Predictors of short- and long-term deterioration in
renal function after partial nephrectomy in patients with
renal cell carcinoma or benign tumour with or without
preoperative predisposition to chronic kidney disease were
studied by S. H. Kim et al. Their findings confirmed our
understanding that abnormal preoperative renal function is
associated with long-term deterioration of renal function
and also indicated the baseline state of the renal func-
tion as the predominant factor affecting the postoperative
functional outcome more than other determinants includ-
ing partial nephrectomy procedure or renal cell carcinoma
itself.
Urothelial bladder cancer remains a lethal malignancy in
a significant proportion of advanced cases; thus more useful
and reliable biomarkers that provide additional prognostic
information are needed. In the quest for the better prognos-
ticator in that group of patients, for the first time S. Ohtake
et al. evaluated an impact of neutrophil-to-lymphocyte ratio
in patients with advanced bladder cancer who received
gemcitabine and nedaplatin therapy. Their findings suggest
that this simple biomarker may serve as a new biomarker
to predict responses to chemotherapy in advanced bladder
cancer patients.
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